Actively recruiting phase 2 trial of PVSRIPO for advanced, PD-1–refractory melanoma

PVSRIPO with or without anti-PD-1 therapy in advanced melanoma following PD-1 failure

The LUMINOS-102 trial is designed to build on the results of the phase 1 trial of PVSRIPO, in which clinical responses were observed in injected and noninjected tumors in patients with unresectable, treatment-refractory melanoma.

Overview of LUMINOS-102

Download the peer-reviewed publication in the Journal for ImmunoTherapy of Cancer with the results of the phase 1 PVSRIPO trial in unresectable, treatment-refractory melanoma


Choose a topic that would better help us get in contact with you

Refer patients to clinical trials

    Participate as a clinical trial site

      Find out more about Istari Oncology